What is the price-to-earnings ratio of Vaccinex?
The price-earnings ratio of Vaccinex is currently 0.
Vaccinex P/S 2024
Vaccinex P/S
0
Ticker
VCNX
ISIN
US9186401033
WKN
A2N30M
As of Oct 4, 2024, Vaccinex's P/S ratio stood at 0, a 0% change from the 69.19 P/S ratio recorded in the previous year.
The Vaccinex P/S history
Vaccinex Aktienanalyse
What does Vaccinex do?
Vaccinex Inc is a biopharmaceutical company based in Rochester, New York, focusing on the development of novel therapies for a variety of diseases. The company was founded in 2001 by Maurice Zylofo and Dr. Steffen Nock, and has since built an impressive track record in drug development. Vaccinex's business model is based on the discovery and development of specific monoclonal antibodies for the treatment of diseases, particularly cancer. The company has developed a proprietary platform technology called ActivMAb®, which quickly and efficiently identifies potential targets and develops specific antibodies to block or modulate these targets. Vaccinex has several business divisions, including cancer therapy, immunology, cardiology, and neurology. Each of these divisions focuses on specific diseases and potential applications of Vaccinex's technology. The company also has partnerships with other industry leaders, such as Bristol-Myers Squibb and Catalent, to support the development and manufacturing of new drugs. The company has conducted several clinical trials to evaluate the efficacy and safety of its products. Vaccinex's most promising products are VX15/2503, a monoclonal antibody targeting cancer, and PEPCON, a potential vaccine for Alzheimer's disease. VX15/2503 is an antibody that targets the semaphorin 4-D receptor, a molecule that plays a key role in cancer development. The drug has shown in preclinical studies that it can inhibit tumor growth and has shown promise in clinical trials for the treatment of lung cancer and an aggressive brain tumor called glioblastoma. PEPCON is a novel vaccine targeting Alzheimer's disease. The vaccine aims to eliminate the beta-amyloid peptide, which is deposited in the brains of patients with Alzheimer's disease. The drug has shown in early clinical studies that it is able to reduce these brain deposits, which may lead to improved cognitive function. Overall, Vaccinex Inc has a promising future and is well-positioned to develop new and innovative therapies for the treatment of diseases. The company has an impressive track record in drug development and partnering with other industry leaders to support the manufacturing and commercialization of new drugs. With a strong pipeline of promising drug candidates, Vaccinex Inc will continue to play an important role in the development of new treatments. Vaccinex ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/S Details
Decoding Vaccinex's P/S Ratio
Vaccinex's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.
Year-to-Year Comparison
Comparing Vaccinex's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.
Impact on Investments
The P/S ratio is instrumental for investors evaluating Vaccinex's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.
Interpreting P/S Ratio Fluctuations
Variations in Vaccinex’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.
Frequently Asked Questions about Vaccinex stock
How has the price-earnings ratio of Vaccinex changed compared to last year?
The price-to-earnings ratio of Vaccinex has increased by 0% fallen (meaning "decreased" or "dropped") compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Vaccinex high compared to other companies?
Yes, the price-to-earnings ratio of Vaccinex is high compared to other companies.
How does an increase in the price-earnings ratio of Vaccinex affect the company?
An increase in the price-earnings ratio of Vaccinex would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Vaccinex affect the company?
A decrease in the price-earnings ratio of Vaccinex would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Vaccinex?
Some factors that influence the price-earnings ratio of Vaccinex are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Vaccinex pay?
Over the past 12 months, Vaccinex paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Vaccinex is expected to pay a dividend of 0 USD.
What is the dividend yield of Vaccinex?
The current dividend yield of Vaccinex is .
When does Vaccinex pay dividends?
Vaccinex pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Vaccinex?
Vaccinex paid dividends every year for the past 0 years.
What is the dividend of Vaccinex?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Vaccinex located?
Vaccinex is assigned to the 'Health' sector.
Wann musste ich die Aktien von Vaccinex kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Vaccinex from 10/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/4/2024.
When did Vaccinex pay the last dividend?
The last dividend was paid out on 10/4/2024.
What was the dividend of Vaccinex in the year 2023?
In the year 2023, Vaccinex distributed 0 USD as dividends.
In which currency does Vaccinex pay out the dividend?
The dividends of Vaccinex are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Vaccinex
Our stock analysis for Vaccinex Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vaccinex Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
